Wednesday, September 4, 2024, Houston, Texas, 11:46 AM – 12:46 PM Central Time (12:46 PM – 1:46 PM Eastern Time)

Data and Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Part 1 of a 2-Part CME Satellite Symposium Series During the Society of Hematologic Oncology 2024 Annual Meeting

Date and Time
Wednesday, September 4, 2024
11:46 AM – 12:46 PM Central Time
Educational Lunch Meeting

Location
George R Brown Convention Center
1001 Avenida de las Americas
Houston, Texas 77010
Phone: (713) 853-8000

Meeting Room
Level 3 in Grand Ballroom C (Theater 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Houston, preregistration is required as seating is limited.  
 
Faculty
Jason Westin, MD, MS
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Professor, Department of Lymphoma and Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Additional faculty to be announced.

Moderator
Matthew Lunning, DO
Associate Professor of Medicine
Medical Director, Cellular Therapy
Associate Vice Chair of Research
Assistant Vice Chancellor for Clinical Research
Division of Hematology/Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska



This CE activity is supported through educational grants from Bristol Myers Squibb and Novartis.
Date and Time
Wednesday, September 4, 2024
11:46 AM – 12:46 PM Central Time
Educational Lunch Meeting

Topics to be announced.

Target Audience
This activity is intended for hematologists, hematology-oncology fellows, medical oncologists and other healthcare providers involved in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Learning Objectives
To be announced.

CE Credit
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation, Support and Credit Statements
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc and Research To Practice. Medical Learning Institute, Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support Statement
This CE activity is supported through educational grants from Bristol Myers Squibb and Novartis.

Physician Continuing Medical Education
Medical Learning Institute, Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure and Conflict of Interest Policy
Medical Learning Institute, Inc, is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy.

FACULTY  — The following faculty reported relevant financial relationships with ineligible entities:

Dr Westin — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Monte Rosa Therapeutics, MorphoSys, Novartis, Seagen Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Kymera Therapeutics, MorphoSys, Novartis, Seagen Inc; Data and Safety Monitoring Board/Committee: Century Therapeutics. Additional faculty to be announced.

MODERATOR  — Dr Lunning — Consulting Honoraria: AbbVie Inc, Acrotech Biopharma, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, CRISPR Therapeutics, Daiichi Sankyo Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Recordati, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, viTToria Biotherapeutics Inc; Research Funding: Bristol Myers Squibb, Fate Therapeutics, Sana Biotechnology.

Planning Committee and Content/Peer Reviewers — The planners and content/peer reviewers from Medical Learning Institute, Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.

This Independent Satellite Symposium is not an official program of the Society of Hematologic Oncology 2024 Annual Meeting. It is not sponsored or endorsed by the Society of Hematologic Oncology.

George R Brown Convention Center
1001 Avenida de las Americas
Houston, Texas 77010
Main Phone: (713) 853-8000

Meeting Room
Level 3 in Grand Ballroom C (Theater 2)

Directions
The George R Brown Convention Center is the main venue for the SOHO 2024 Annual Meeting.

 
This activity is intended for hematologists, hematology-oncology fellows, medical oncologists and other healthcare providers involved in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.

There is no fee to participate in this hybrid event. In order to attend the in-person symposium in Houston, you must also be registered to attend the SOHO 2024 Annual Meeting. Preregistration (below) is required as seating is limited for this program.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.